Certara Inc.

# Signal Note: Deerfield Initiates $68.8M Position in Certara Deerfield's entry into CERT signals confidence in the drug modeling/simulation software platform's recurring revenue model and potential margin expansion, particularly as pharma clients accelerate virtual trial designs to reduce development timelines post-COVID normalization. The position size ($68.8M, ~7.8M shares at ~$8.80/share) suggests conviction in either near-term contract wins with major pharma or confidence in the company's AI-enhanced capabilities to defend against competition from larger ERP vendors. No immediate catalyst disclosed, but timing aligns with biotech's continued shift toward computational approaches to address rising clinical trial costs.